BPC-157, MOTS-c and Other Peptides With Semaglutide or Tirzepatide

No study has tested BPC-157, MOTS-c, TB-500, KPV, Epitalon or Semax in people who are also on a GLP-1 drug, whether semaglutide (sold as Ozempic and Wegovy) or tirzepatide (Mounjaro and Zepbound). A search of PubMed and ClinicalTrials.gov in October 2026 found no trial, finished or recruiting, that pairs any of the six with a GLP-1 drug. So when a clinic or a forum says the combination is safe, nobody has measured that. What is known comes from the GLP-1 labels, which warn that these drugs slow the stomach and can change how other oral medicines are absorbed,^[3][5] and from the HHS policy of October 28, 2026, which covers licensed pharmacies compounding the six peptides only as single-ingredient products on an individual prescription.^[1]

Has anyone studied these peptides together with a GLP-1?

PubMed lists a handful of papers that mention BPC-157 or MOTS-c in the same text as semaglutide or tirzepatide. Read closely, they are narrative reviews that discuss the drugs side by side, a 2024 survey of clinic websites, a mouse study, and a study that measured the body’s own MOTS-c levels in people with diabetes. None gave a peptide to people on a GLP-1 drug and measured what happened. ClinicalTrials.gov has no registered study combining them either.

The only listings for MOTS-c and TB-500, and one of the BPC-157 listings, come from a sponsor whose TB-500 record opens with the words “This fictional study is an example of a ClinicalTrials.gov-style record,” so neither MOTS-c nor TB-500 has a credible registered trial.^[2] For anyone thinking of adding MOTS-c to tirzepatide, that leaves nothing to go on: if blood sugar, weight or side effects change, there is no way to tell which drug did it.

Each peptide’s own evidence is thin before any GLP-1 enters the picture. FDA’s 2026 review of MOTS-c found no human study of the peptide by any route and called its risks in people unknown.^[7] A 2026 review in Missouri Medicine contrasted semaglutide and tirzepatide, which it described as evidence-based, with BPC-157 and TB-500, which it said lack established human safety profiles.^[14] The evidence pages for MOTS-c and BPC-157 go through what exists.

What the GLP-1 labels say about taking other medicines

None of the four labels names a peptide. They do describe two general interactions, and both apply to anything else a person takes.

Slower stomach emptying. The labels for Ozempic and Wegovy^[3][4] and for Mounjaro and Zepbound^[5][6] all say the drug delays gastric emptying, so it may change how oral medicines taken at the same time are absorbed. The semaglutide labels add that in clinical pharmacology studies of the injection, the oral medicines tested showed no clinically relevant change in absorption, but both still call for caution or monitoring. The Wegovy label also reports that the semaglutide tablet raised levothyroxine exposure by 33% in an interaction study.^[3][4] The tirzepatide labels tell prescribers to use caution with oral medicines, to monitor drugs that only work above a threshold concentration or have a narrow therapeutic index (warfarin is the example), and to tell people on birth control pills to change method, or use condoms as a backup, during the first four weeks and for four weeks every time the dose goes up.^[5][6]

Low blood sugar with other glucose-lowering drugs. The labels warn that combining a GLP-1 drug with insulin or a sulfonylurea raises the risk of hypoglycemia, including severe hypoglycemia, and tell prescribers to consider lowering the insulin or sulfonylurea dose.^[3][4][5] That warning is about approved diabetes drugs. It matters for peptides only where a peptide is sold to lower glucose, which brings in MOTS-c (below).

Our GLP-1 drug interaction checker covers approved medicines that have interaction data. Unapproved peptides have none, so a blank result for BPC-157 means nobody has looked, and says nothing about safety.

Oral BPC-157 and KPV on a drug that slows the stomach

Two of the six can be compounded as something you swallow. The HHS policy covers BPC-157 as an injection, a topical or an oral product, and KPV only as a topical or oral product.^[1] For oral forms the policy itself flags a problem: it calls oral absorption of peptides “inherently difficult and complex” and expects the pharmacy to keep documentation that the specific oral formulation reaches an adequate level in the human body.^[1]

Add a GLP-1 drug and there is a second unknown. Semaglutide and tirzepatide hold food and pills in the stomach longer, and peptides are broken down by digestive enzymes. Whether that longer stay changes how much oral BPC-157 or KPV survives has never been measured, in either direction. Anyone offered capsules should ask the pharmacy for its oral bioavailability documentation; oral BPC-157 capsules covers what is known about the capsule form, and KPV: what the evidence shows covers KPV.

MOTS-c and its metabolic claims, next to the GLP-1 evidence

MOTS-c is a common pairing with a GLP-1, because sellers market it for the same goals: glucose control, insulin sensitivity and weight loss. FDA’s review lists those claims from seller websites and notes that MOTS-c is marketed both alone and combined with other substances.^[7] The evidence behind each drug is of a different kind; peptides for weight loss ranks every peptide sold for weight by its human evidence.

Adding MOTS-c to a GLP-1 drug, then, puts a peptide with mouse data on top of drugs with large human trials. If the mouse glucose effect does carry over to people, it would overlap with a GLP-1’s own glucose lowering, and the labels already warn about stacking glucose-lowering drugs.^[3][7] Whether that happens is unknown. It is one reason a person with diabetes, especially one also on insulin or a sulfonylurea, should not add MOTS-c without the prescriber who manages their diabetes knowing.

One study does connect GLP-1 drugs and MOTS-c, though it says nothing about injecting the peptide. Greek researchers measured the body’s own MOTS-c in 163 people with type 2 diabetes over a year. Liraglutide alone did not raise it; an SGLT2 inhibitor did, alone or combined with liraglutide.^[12] For dose and side-effect data on MOTS-c itself, see MOTS-c dosage and side effects and the seller profile at /peptides/mots-c.

BPC-157 for GLP-1 nausea and stomach side effects

The most common pitch for BPC-157 alongside semaglutide is that it soothes the gut while the GLP-1 drug causes nausea, constipation or reflux. That claim rests on animal studies of BPC-157 in stomach and intestinal injury. No study has given BPC-157 to people with GLP-1 side effects, and no registered trial plans to. Starting a new peptide during GLP-1 dose increases also makes it harder to tell whether a change in nausea or appetite came from the dose or from the peptide. The same goes for TB-500, which is sold for recovery and has one recruiting human trial, on cardiovascular markers. /peptides/bpc-157 shows how sellers present it.

Why clinics sell GLP-1 and peptide bundles

Bundles predate the HHS policy. In a study of 93 Colorado websites selling compounded GLP-1 drugs, searched in March and April 2024, eight advertised combination products with B vitamins, and one advertised a product compounded with BPC-157, which the authors noted FDA had found unsafe for compounding at the time. Forty-one of the 93 sites referred to FDA approval when describing compounded products that are not FDA-approved.^[13] None of these combinations has been tested in a trial. Our page on tirzepatide with glycine, B6 or niacinamide covers the additive version of the same idea.

The HHS policy leaves combinations out. It covers only the six peptides, only at state-licensed 503A pharmacies (it excludes larger 503B outsourcing facilities^[15]), only on a patient-specific prescription, and only when the product “contains only a single Active Pharmaceutical Ingredient” from its list.^[1] The stated reason is safety surveillance: when each product holds one ingredient, a side effect can be traced to the substance behind it.^[1] A vial that mixes semaglutide or tirzepatide with BPC-157 or MOTS-c falls outside the policy, and so does a peptide-plus-peptide blend. The policy is also temporary, lasting until FDA decides each peptide in a final rule, and it is not FDA approval.^[1] Supply may be slow. The head of a Florida compounding company told NPR, “We won’t be able to meet demand.”^[15] For how blends are sold, see peptide blends and stacks.

What to ask before adding a peptide to semaglutide or tirzepatide

• Separate prescriptions and separate products? Each peptide should be a separate, single-ingredient product on a separate prescription, and the policy requires its label to say it is compounded and not for resale.^[1] A combined GLP-1 and peptide vial is outside the HHS policy.
• Does the prescriber of your GLP-1 know? If a second clinic adds the peptide, the doctor managing your semaglutide or tirzepatide may not see it. Tell them, especially if you also take insulin, a sulfonylurea or a drug with a narrow therapeutic index.^[5]
• Which pharmacy makes it, and can it show a certificate of analysis? The policy requires ingredients from an FDA-registered facility with a lot-specific certificate of analysis.^[1] Research-use-only vials sold online meet none of these conditions; see what peptide therapy is for the difference.
• For capsules: where is the oral bioavailability documentation? The policy expects the pharmacy to have it for every oral peptide.^[1]
• Who monitors, and with what tests? Ask what baseline and follow-up labs are planned, who reviews them, and what result would stop the peptide. Peptide blood work and monitoring lists what is and is not standard.
• How do you report a side effect? Under the policy, the pharmacy has to send reports of serious side effects to MedWatch, FDA’s reporting system, and instructions for reporting problems should be on the patient labeling.^[1] Patients and clinicians can also report directly to MedWatch.^[16]
• One change at a time? If you start a peptide while still raising your GLP-1 dose, neither you nor your prescriber can tell which drug caused a new symptom.